Allissa Joseph
Family · Kinder, LANPI 1487179818
Payments from drug & device makers
Across 92 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$512
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$321
- Axsome Therapeutics, Inc.$249
- Supernus Pharmaceuticals, Inc.$240
- Gilead$143
- Novo Nordisk$119
- plus $598 from 15 others
What the payments were for
- Food & beverage$2,02893%
- Education$1557%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $512 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $321 |
| Axsome Therapeutics, Inc. | 8 | $249 |
| Supernus Pharmaceuticals, Inc. | 3 | $240 |
| Gilead | 2 | $143 |
| Novo Nordisk | 5 | $119 |
| Lilly USA, LLC | 5 | $95 |
| Bayer | 5 | $70 |
| Astellas Pharma US Inc | 3 | $63 |
| Vanda Pharmaceuticals Inc. | 3 | $57 |
| AstraZeneca | 3 | $49 |
| Boston Scientific | 1 | $41 |
| Exact Sciences | 2 | $37 |
| Novartis | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Johnson & Johnson | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Pfizer | 1 | $20 |
| Evofem Biosciences, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,183 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 19 | $20,007 |
| OzempicSemaglutide | 14 | $13,424 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $2,759 |
| Sucralfate | 13 | $2,213 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,045 |
| Atorvastatin Calcium | 106 | $1,077 |
| Gabapentin | 49 | $652 |
| Diclofenac Sodium | 37 | $550 |
| Levothyroxine Sodium | 43 | $486 |
| Fluticasone Propionate | 52 | $465 |
| Omeprazole | 45 | $446 |
| Lisinopril | 81 | $437 |
| Pantoprazole Sodium | 47 | $369 |
| Montelukast Sodium | 30 | $332 |
| Metformin Hcl ErMetformin Hcl | 31 | $314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $95 | $20,00719 claims |
| Novo NordiskOzempic | $119 | $13,42414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.
Other family in Kinder
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.